140 related articles for article (PubMed ID: 38044835)
1. Granulocyte Colony-Stimulating Factor (Neupogen®; Filgrastim) Accelerates Neutrophil Recovery in a Rodent Model of Sulfur Mustard-Induced Hematologic Toxicity.
Beske PH; Harvilchuck JA; Gibbs ST; Green CE; Iyer L; O'Loughlin K; Hu TC; Nealy MS; Platoff GE; Yeung DT
Disaster Med Public Health Prep; 2023 Dec; 17():e550. PubMed ID: 38044835
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.
Crobu D; Spinetti G; Schrepfer R; Tonon G; Jotti GS; Onali P; Dedoni S; Orsini G; Di Stefano A
BMC Pharmacol Toxicol; 2014 Feb; 15():7. PubMed ID: 24555723
[TBL] [Abstract][Full Text] [Related]
3. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.
MacVittie TJ; Bennett AW; Farese AM; Taylor-Howell C; Smith CP; Gibbs AM; Prado K; Jackson W
Health Phys; 2015 Nov; 109(5):427-39. PubMed ID: 26425903
[TBL] [Abstract][Full Text] [Related]
5. A Rodent Model of Sulfur Mustard Hematologic Toxicity for the Efficacy Evaluation of Candidate Medical Countermeasures.
Beske PH; Wilhelm CM; Harvilchuck JA; Platoff GE; Yeung DT
Mil Med; 2022 Jan; 187(1-2):e106-e115. PubMed ID: 33346363
[TBL] [Abstract][Full Text] [Related]
6. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC; Crawford J; Klippel Z; Reiner M; Osslund T; Fan E; Morrow PK; Allcott K; Lyman GH
Support Care Cancer; 2018 Jan; 26(1):7-20. PubMed ID: 28939926
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
8. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation.
Zecchini J; Yum K; Steinberg A; Smith C; Kim S
Support Care Cancer; 2018 Mar; 26(3):1013-1016. PubMed ID: 28990128
[TBL] [Abstract][Full Text] [Related]
9. Safety and Biosimilarity of ior
Licollari A; Riddle K; Taylor SR; Ledon N; Bolger GT
J Pharm Sci; 2017 Jun; 106(6):1475-1481. PubMed ID: 28238900
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Neulasta or Neupogen on H-ARS and GI-ARS Mortality and Hematopoietic Recovery in Nonhuman Primates After 10-Gy Irradiation With 2.5% Bone Marrow Sparing.
Farese AM; Bennett AW; Gibbs AM; Hankey KG; Prado K; Jackson W; MacVittie TJ
Health Phys; 2019 Mar; 116(3):339-353. PubMed ID: 30281533
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
[TBL] [Abstract][Full Text] [Related]
13. The Time Course of Radiation-induced Lung Injury in a Nonhuman Primate Model of Partial-body Irradiation With Minimal Bone Marrow Sparing: Clinical and Radiographic Evidence and the Effect of Neupogen Administration.
MacVittie TJ; Farese AM; Parker GA; Jackson W
Health Phys; 2019 Mar; 116(3):366-382. PubMed ID: 30624350
[TBL] [Abstract][Full Text] [Related]
14. EFFICACY OF HUMAN RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF, FILGRASTIM; NEUPOGEN
Davis MR; Leger JS; Croft L; DiRocco S; Gearhart S; Osborn S; Schmitt T; Nollens H
J Zoo Wildl Med; 2021 Sep; 52(3):1042-1053. PubMed ID: 34687523
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
Lyman GH
Expert Opin Biol Ther; 2005 Dec; 5(12):1635-46. PubMed ID: 16318427
[TBL] [Abstract][Full Text] [Related]
18. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
del Giglio A; Eniu A; Ganea-Motan D; Topuzov E; Lubenau H
BMC Cancer; 2008 Nov; 8():332. PubMed ID: 19014494
[TBL] [Abstract][Full Text] [Related]
19. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
[TBL] [Abstract][Full Text] [Related]
20. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
